

518.993

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization International Bureau



21 DEC 2004



(43) International Publication Date
31 December 2003 (31.12.2003)

PCT

(10) International Publication Number
WO 2004/000044 A1

(51) International Patent Classification⁷: A23L 1/307 TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(21) International Application Number:

PCT/DK2003/000424

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(22) International Filing Date: 23 June 2003 (23.06.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
PA 2002 00959 21 June 2002 (21.06.2002) DK
60/402,529 12 August 2002 (12.08.2002) US

(71) Applicant (for all designated States except US): MN PHARMA A/S [DK/DK]; c/o Renneberg ApS, Åbrikken 157, DK-2830 Virum (DK).

(72) Inventors; and

(75) Inventors/Applicants (for US only): ASTRUP, Arne [DK/DK]; Fabritius Allé 4, DK-2930 Klampenborg (DK). TOUBRO, Søren [DK/DK]; Tempelvej 26, DK-4390 Vipperød (DK).

(74) Agent: HØIBERG A/S; St. Kongensgade 59 A, DK-1264 Copenhagen (DK).

(81) Designated States (national): AE, AG, AL, AM, AT (utility model), AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ (utility model), CZ, DE (utility model), DE, DK (utility model), DK, DM, DZ, EC, EE (utility model), EE, ES, FI (utility model), FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)

— of inventorship (Rule 4.17(iv)) for US only

Published:

— with international search report
— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: LOW-ENERGY-DIET

(57) Abstract: The invention relates to a low-energy diet (LED) having effect on the basal metabolic rate, the protein metabolism and/or the energy expenditure, such as a low-energy-diet comprising Carbohydrate: 70-120 g, Protein: 50-80 g, Fat: 5-20 g, including medium chain triglycerides, and Iron: 20-30 mg/d, wherein the carbohydrate source and/or the fat source may increase the energy expenditure.

WO 2004/000044 A1

Low-energy-diet**Field of invention**

5 The present invention relates to a low-energy diet (LED) having effect on the basal metabolic rate, the protein metabolism and/or the energy expenditure.

All patent and non-patent references cited in the application, or in the present application, are also hereby incorporated by reference in their entirety.

10

Background of invention

Low-energy-diets are known from the prior art, for example EP 425 423 presents a low-energy-diet wherein specific fat, carbohydrate and protein sources are used.

15 However, the low-energy-diets known either simply offer fewer calories than normal daily cost, or focus on one mechanism of losing weight.

Summary of invention

20 The present invention relates to a low-energy-diet having several improvements in relation to prior art diets.

The present diet is capable of increasing satiety yet providing weight loss. Furthermore, the diet maintains fat-free body mass, increases the energy expenditure, reduces or eliminates risk of iron deficiency, as well as magnesium and calcium deficiency.

In a preferred embodiment the diet also prevents heart arrhythmias and gall stones.

30 Accordingly, the present invention relates to a low-energy-diet comprising as ingredients sources of

35 protein, carbohydrate, fat, and optionally minerals and pH-regulating agents, wherein one or more of the ingredient(s) has effect on at least two of the following mechanisms

the basal metabolic rate, and/or
the protein metabolism, and /or
the energy expenditure,

5

when the low-energy-diet is administered as the main or sole nutrition.

10 The low-energy-diet is in particular intended for use as the main or sole nutrition in the treatment of overweight, by for example replacing one or more, or all of the daily meals of an individual being obese. But the diet may of course also be used as a nutritional supplement.

15 In another aspect the invention relates to a method for treating overweight comprising administering to an individual in need thereof an effective amount of a low-energy-diet as defined above as the main or sole nutrition daily, in particular the low-energy-diet is suitable for treatment of severe overweight also called obesity.

In the present context "overweight" is defined as a Body mass Index $> 25\text{kg/m}^2$.
"Severe overweight" is defined as a body mass Index $> 30 \text{ kg/m}^2$.

20

Furthermore, the invention relates to the use of ingredients being sources of
25 protein, carbohydrate, fat, and optionally minerals and pH-regulating agents, wherein one or more of the ingredient(s) has effect on at least two of the following mechanisms

the basal metabolic rate, and/or
the protein metabolism, and /or
the energy utilization,

30

for the production of a low-energy-diet for administration as the main or sole nutrition.

35

Drawings

Fig 1. Least Squares Means (SE) body weight of subjects during weight reduction by either high (black triangle, n=19) or low physical activity (open triangle, n=22), and the overall mean values (---, n=41). There were no differences between interventions, thus a significant effect of time (trend, P<0.0001), with an overall slope β (95% confidence limits): $\beta = -1.08$ kg/week (-1.22 -0.95).

Fig. 2. Percentage weight loss during 7 weeks intervention using Speasy® as the only nutrient. Values are Least Squares Means (95% confidence limits (---)) n=41 observations. Trend P<0.0001; Slope β (95% confidence limit): $\beta = 1.186$ %weight loss/week (1.063 – 1.309).

Detailed description of the invention

15

Definitions

Daily amounts: In the present context the amounts of ingredients in the low-energy-diet is given as daily doses, i.e. for example as mg/d. Since the low-energy-diet may 20 be divided into two or more doses per day, the amount of the various ingredients are calculated on basis of the total low-energy-diet per day.

It is an object of the present invention to provide a diet having an improved profile as compared to prior art diets in respect of at least the following parameters:

25 satiety

weight loss

maintaining fat-free body mass

increase in energy expenditure

30 This is obtained by using ingredients in the low-energy-diet that is capable of, preferably in a synergistic manner, to have effect on at least two of the following mechanisms

the basal metabolic rate, and/or

35 the protein metabolism, and /or

the energy expenditure,

when the low-energy-diet is administered as the main or sole nutrition.

5 In a preferred embodiment the low-energy-diet is capable of having effect on all three of the following mechanisms

the basal metabolic rate,

the protein metabolism,

10 the energy expenditure,

when the low-energy-diet is administered as the main or sole nutrition.

Low-energy-diets administered to treat overweight are often taken for a long period of time, and therefore it is of importance that basal metabolic rate as well as protein metabolism is only mildly affected by the diet, if at all effected, so that the metabolism is stabilised although an individual to lose weight administer the low-energy-diet as main or sole nutrition for weeks or months. Thus, it is preferred that the ingredients having effect on the basal metabolic rate are capable of inhibiting the basal metabolic rate from decreasing. The ingredients having effect on the protein metabolism are preferably capable of reducing protein degradation.

Furthermore, the ingredients having effect on energy expenditure are preferably capable of increasing the energy expenditure.

25

Energy content

In any diet form aiming at promoting weight loss, the diet is a balance between offering sufficiently low amount of energy and at the same time offering satiety sufficiently high to maintain the individual losing weight to follow the instructions of the diet.

In the present invention, the diet preferably has an energy content in the range of from 600 kcal/d to 1200 kcal/d, such as an energy content of approximately 800 kcal/d.

35

Basal metabolic rate

During a diet, in particular a low-energy-diet, the normal response in the body, is to
5 lower the basal metabolic rate, due to the lower level of energy supply. However, when aiming at losing weight this normal reduction in the basal metabolic rate counteracts to some extent the effect of less energy intake. Accordingly, it is an object of the invention to prevent reduction in the basal metabolic rate.

10 In one embodiment this is accomplished by providing an iron content in the low-energy-diet, wherein said iron content is sufficient to prevent reduction in the basal metabolic rate, as discussed below.

15 Basal metabolic rate may be measured by indirect calorometry either by a ventilated hood system or by use of respiration chambers.

Protein metabolism

Normal metabolic responses to low-energy-diet are ketosis followed by acidosis
20 leading to protein loss. According to the present invention, it is preferred to supply proteins in the diet, and also to supply with an ingredient capable of reducing or eliminating the protein loss, normally seen in individuals subjected to low-energy-diets.

25 The effect of an ingredient on the protein metabolism may be measured as the effect on the nitrogen metabolism, for example as described in Stanko et al. "Body composition, energy utilization, and nitrogen metabolism with a severely restricted diet supplemented with dihydroxyacetone and pyruvate", Am J Clin Nutr (1992) 55, 771-6, hereby incorporated by reference.

30 The ingredient capable of reducing or eliminating the protein loss, preferably is an ingredient capable of reducing the acidosis following ketosis, thereby reducing the protein degradation, and as effect affecting the protein metabolism.

pH regulation

One such protein metabolism effecting ingredient is this a pH-regulating ingredient. Accordingly, the low-energy-diet according to the invention preferably comprises a pH-regulating agent in an amount sufficient to reduce protein degradation. In a preferred embodiment the pH-regulating agent is bicarbonate in an amount sufficient to reduce protein degradation, such as bicarbonate in an amount of from 50 mmol/d to 70 mmol/d.

10 Protein

The protein content of the low-energy diet is preferably given in the amounts recommended by the health authorities. The protein source is preferably a source of proteins having a great bio-availability.

15 Thus, the source of protein is preferably selected from casein, pork protein, and/or soy protein. In a preferred embodiment at least a portion of the source of protein is soy protein.

20 In the low-energy-diet having a energy content of about 600 kcal/d to 1200 kcal/d the protein content is preferably in an amount of from 60 g protein to 75 g protein, such as about 70 g protein.

Energy expenditure

25 Daily energy expenditure may be measured by indirect calorimetry during stay in a respiratory chamber as described in Dulloo et al. "Twenty-four-hour energy expenditure and urinary catecholamines of humans consuming low-to-moderate amounts of medium-chain triglycerides: a dose-response study in a human respiratory chamber, European Journal of Clinical Nutrition (1996) 50, 152-158, hereby incorporated by reference.

30 In order to promote the desired weight loss in individuals subjected to the low-energy diet, the low-energy-diet preferably also comprises at least one ingredient capable of increasing the energy expenditure.

This ingredient may be selected from one or more of the following:

Dihydroxy acetone phosphate, pyruvate, as well as medium chain triglycerides.

5

Accordingly, the low-energy-diet according to the invention preferably comprises as at least a part of the carbohydrate source dihydroxy acetone phosphate and/or pyruvate.

10 The dihydroxy acetone phosphate and/or pyruvate is preferably in an amount sufficient to increase the energy expenditure whether administered together or alone. Therefore, the diet preferably comprises dihydroxy acetone phosphate in an amount of from 5 g to 15 g, such as in an amount of from 10 g to 15 g. In another embodiment the diet preferably comprises pyruvate in an amount of from 5 g to 20 g, such as in an amount of from 10 g to 20 g.

15

The same amounts of dihydroxy acetone phosphate and pyruvate may also be administered when the two ingredients both are administered in the low-energy-diet.

20

The pyruvate preferably is in the form of sodium pyruvate and/or calcium pyruvate, for example as about 10 g of sodium pyruvate and 9 g of calcium pyruvate.

Carbohydrate

25

In addition to the carbohydrates given as pyruvate and dihydroxy acetone phosphate other sources of carbohydrate are also included in the low-energy-diet. Any suitable carbohydrate source may be used, for example fructose.

30

The low-energy-diet according to the invention preferably comprises the total carbohydrate source in an amount of from 70 g carbohydrate to 120 g carbohydrate, more preferably in an amount of from 80 g carbohydrate to 110 g carbohydrate.

Fat

Another ingredient capable of promoting the energy expenditure is medium chain tri-glycerides as discussed above, said medium chain triglycerides preferably being

5 selected from C6 triglycerides, C8 triglycerides and C10 triglycerides.

Of the preferred amount of fat source in the low-energy-diet according to the invention in an amount of from 5 g to 20 g, the medium chain triglycerides preferably constitute at least 3 g of the fat source.

10

The remaining fat in the fat source is preferably unsaturated fatty acids, such as oleic acid.

Also, the low-energy-diet may comprise fish oil, such as at least 1 g of fish oil, such

15 as at least 3 g of fish oil, such as at least 5 g of fish oil.

Iron content

In a preferred embodiment the low-energy-diet according to the invention comprises

20 iron in an amount sufficient to modulate the basal metabolic rate, such as sufficient to prevent reduction in the basal metabolic rate. In Beard et al. "Changes in iron status during weight loss with very-low-energy diets" Am J Clin Nutr (1997) 66, 104-10 the effect of iron intake during weight loss is described. The saturation of transferrin is increased when the iron intake is increased to above the recommended 25 daily allowance (RDA) leading to a reduced decrease in the thyroid hormone T₃ level. Thereby the reduction in basal metabolic rate normally seen in individuals during a diet, in particular a low-energy-diet is reduced or even eliminated.

It is preferred that at least 2 mg/d iron above RDA should be included in the low-

30 energy-diet, such as at least 5 mg/day iron above RDA. Most preferably about 9 mg/d iron above RDA should be included in the low-energy-diet. In other words, the low-energy-diet according to the invention preferably comprises iron in an amount of from 20 mg/d to 30 mg/d.

Satiety

Apart from stabilising the basal metabolic rate and the protein metabolism and increasing the energy expenditure, the low-energy-diet should preferably also provide
5 the individual subjected to the low-energy-diet with a feeling of satiety each time the doses of low-energy-diet is taken. Thereby the probability of success of losing weight rapidly increases.

10 The ingredients, dihydroxy acetone phosphate, pyruvate and medium chain triglycerides, capable of increasing the energy expenditure may additionally have the effect of providing satiety.

Dietary fibres

15 In addition to the ingredients mentioned above, the low-energy-diet according to the invention may further comprise dietary fibres, among others also to increase the feeling of satiety.

20 The dietary fibres may be any suitable dietary fibres, such as fibres are selected from barley fibres, sugar beat fibres, and oat fibres or combinations thereof.

Independent of the fibre used, the amount of fibre is preferably in an amount of from 10 g/d to 50 g/d.

25 **Magnesium**

In order to avoid disturbances in the electrolytes leading to heart arrhythmias it is further preferred that the diet comprises magnesium, such as magnesium added as MgCl, preferably in an amount of from 15 mEq/d to 20 mEq/d, preferably about 18
30 mEq/d.

Ursodeoxy cholic acid

35 The changes in the organism of an individual losing weight by means of a low-energy-diet may lead to side effects such as gall stones. In a preferred embodiment

the diet further comprises ursodeoxy cholic acid to reduce the risk of gall stones. In another embodiment ursodeoxy cholic acid is administered separately as a tablet. In any event the ursodeoxy cholic acid is preferably administered in an amount of from 1000 mg/d to 1400 mg/d, preferably about 1200 mg/d.

5

Vitamins and minerals

Vitamins and minerals not mentioned above are dosed within the limits laid down by the health authorities, and may be included in the low-energy-diet or administered daily in tablet form. In particular vitamins and minerals are dosed according to Dietary Reference Intakes, Institute of medicine, USA, with modifications according to special requirements for overweight subjects on a low-calorie diet.

In a preferred embodiment the low-energy-diet according to the invention comprises per day

Carbohydrate: 70-120 g, including dihydroxy acetone phosphate 10-15g and/or pyruvate 10-20 g

Protein: 50-80 g

Fat: 5-20 g, including at least 3 g medium chain triglycerides

Iron: 20-30 mg/d

In another embodiment the low-energy-diet according to the invention comprises per day

Carbohydrate: 70-120 g,

Protein: 50-80 g

Fat: 5-20 g, including at least 4 g medium chain triglycerides

Iron: 20-30 mg/d

30

In a more preferred embodiment, the low-energy-diet according to the invention comprises per day

Carbohydrate: 70-120 g, including dihydroxy acetone phosphate 10-15g and/or pyruvate 10-20 g

Protein: 50-80 g

Fat: 5-20 g, including at least 3 g medium chain triglycerides

Iron: 20-30 mg/d

Magnesium: 15-20 mEq/d

5

In an even more preferred embodiment the low-energy-diet according to the invention comprises per day:

Carbohydrate: 70-120 g, including dihydroxy acetone phosphate 10-15g and/or pyruvate 10-20 g

10 Protein: 50-80 g

Fat: 5-20 g, including at least 3 g medium chain triglycerides

Iron: 20-30 mg/d

Magnesium: 15-20 mEq/d

15 Fibres: 10-50 g/d

Formulation

The low-energy-diet according to the present invention may be formulated into any suitable form, such as powders, or ready-to-drink or ready-to-eat products. Thereby the individuals desiring to lose weight may adapt more to the diet, since they have a choice between various products.

In one embodiment the low-energy-diet is in the form of powder. Said powder may be dispensed in separate doses and suspended or solved in liquid, such as liquid selected from water and milk immediately before intake.

In another embodiment the low-energy-diet is formulated as a ready-to-drink product

25 30 In yet another embodiment the low-energy-diet is formulated as a bar

Applications

The low-energy-diet according to the invention is in particular meant for use in the treatment of overweight. Accordingly, the present invention further relates to a

method for treating overweight comprising administering to an individual in need thereof an effective amount of a low-energy-diet as defined above as the main or sole nutrition daily.

5 The diet is preferably divided into two or more portions per day to be administered at regular times for, for example to simulate the traditional meal times.

Another aspect of the invention relates to the use of ingredients being sources of

10 protein, carbohydrate, fat, and optionally minerals and pH-regulating agents, wherein one or more of the ingredient(s) has effect on at least two of the following mechanisms

15 the basal metabolic rate, and/or
the protein metabolism, and /or
the energy expenditure,

20 for the production of a low-energy-diet for administration as the main or sole nutrition.

25 The ingredients mentioned may be as described above.

The diet is preferably packed in a package intended for being able to cover the total nourishment requirement for a defined period of time, such as packages for a powder, a ready-to-drink product or a bar product.

Examples

Example 1

30 Powder formulation

A daily dose of the low-energy-diet

35 Carbohydrate: 96 g, including pyruvate 10 g

Protein (soy and casein): 70 g
 Fat (oleic acid): 15 g
 Fibres (barley): 15 g/d
 Vitamins and minerals according to Nordis Alimantaris
 5 Plus extra addition of iron: 16 g
 Flavours: 3 g

Example 2

10 Ready-to-drink formulation with vanilla flavour

	Formula	%
	Water	74.8
15	Corn Syrup Solids, 24	8.2
	Carbohydrate including pyruvate (10% of total)	6.8
	Protein (casein and soy 50/50)	7.22
	Oil (oleic acid)	1.146
	Lecithin	0.4
20	Dicalcium phosphate	0.3
	Avicel, FMC CL611	0.241
	Vanilla flavours	0.460
	Ca citrate	0.134
	Mono potassium phosphate	0.096
25	Butterscotch	0.05
	WSV premix	0.048
	Viscarin	0.02
	OSV premix	0.019
		100.0

30 **Example 3**

Ready-to-eat product – bar with vanilla flavour

	Formula	%
35		

Water	82.2
Carbohydrate including pyruvate (10% of total)	8.49
Protein (casein and soy 50/50)	8.33
Avicel, FMC CL611	0.46
5 Vanilla Flavours	0.4
Butterscotch	0.08
Viscarin	0.04

Example 4

10

Production of powder formulation

A powder formulation consisting of the ingredients of table 1 were produced by mixing the ingredients and homogenising the powder.

15

Table 1

Content	Units	Content in daily amount	Recommended daily amount
Energy	kcal	810	800
	KJ	3400	3400
Protein	g	75	
Soy protein	E%	37	
Carbohydrates	g	96	
	E%	44	
Fat	g	15	
	E%	16	
Linolic acid	g	4.2	
Linolenic acid	g	0.8	
unsaturated fatty acid	g	7.0	
Including MCT	g	4.0	
Fibres (barley)	g	12	
Vitamins			
Vitamin A	mg	1,0	1-1,5

Vitamin D	µg	10	5-7.5
Vitamin E	mg	15	10-15
Vitamin K	µg	70	70-140
Tiamin	mg	1,2	1.4-2.1
Riboflavin	mg	1,6	1.7-2.6
Niacin	mg	18	18-27
Vitamin B6	mg	1,5	2.1-3.2
Vitamin B12	µg	2,4	3.0-4.5
Folacin	µg	400	200-300
Biotin	µg	100	100-200
Pantotenic acid	mg	5	4-7
Vitamin C	mg	90	60-90
Minerals / salts			
Sodium (Na)	mg	1685	1100-3300
Potassium (K)	mg	3100	1900-5600
Calcium (Ca)	mg	1200	800-1200
Chloride (Cl)	mg	1700	1700-5100
Phosphor (P)	mg	700	620-1860
Magnesium (Mg)	mg	350	350-525
Iron (Fe)	mg	22	15-23
Zinc (Zn)	mg	12	12-18
Copper (Cu)	mg	2	2-3
Iodine (I)	µg	150	150-225
Mangan (Mn)	mg	2,5	2.5-5
Chrom (Cr)	µg	50	50-100
Selen (Se)	µg	55	50-100
Molybden (Mo)	µg	150	150-300

Aromatics	mg	5	
Total	mg	220	

Example 5

Weight loss with a powder formulation

5

41 subjects were allocated to weight reduction intervention with a powder formulation as described in Example 4, and allocated to either low or high physical activity during the intervention, the subjects were as described in Table 2.

10 **Table 2.** Anthropometry for all 41 subjects entering weight reduction intervention with the formulation as described in Example 4

		A (n=19)	B (n=22)	*P-value
15	Age (years)	42.4 ± 6.03 (32 – 54)	44.0 ± 8.4 (28 – 59)	0.475
20	Height (m)	1.67 ± 0.06 (1.57 – 1.78)	1.65 ± 0.07 (1.51 – 1.77)	0.488
25	Weight (kg)	90.94 ± 8.57 (77.00 – 109.00)	90.55 ± 11.53 (64.00 – 106.00)	0.903
30	Fat free mass (kg)	51.7 ± 3.2 (46.2 – 61.0)	51.7 ± 5.8 (37.8 – 63.6)	0.996
	Fat mass (kg)	39.2 ± 6.6 (28.6 – 48.6)	38.9 ± 6.7 (26.2 – 48.8)	0.853
35	Pct Fat (%Body weight)	43 ± 4 (36 – 48)	42 ± 3 (35 – 48)	0.876

Body mass index (kg/m ²)	32.8 ± 3.7 (27.0 – 40.0)	33.0 ± 3.3 (28.0 – 38.0)	0.817
--------------------------------------	-----------------------------	-----------------------------	-------

5 Values are mean ± SD (min – max)

A: Subjects high in physical activity

B: Subjects low in physical activity

*: Analyzed using One-way ANOVA

10 The intervention lasted for 7 weeks, and the changes due to intervention after 7 weeks, using the formulation as described in Example 4 as the only nutrient is listed in Table 3.

15 **Table 3.**

	A (n=19)	B (n=22)	*P-value
Weight (kg)	-6.75 (-7.89 – -5.61)a	-6.73 (-7.82 – -5.64)a	0.984
20 Fat free mass (kg)	-1.6 (-2.5 – -0.7)b	-2.4 (-2.89 – -1.86)a	0.125
Fat mass (kg)	-5.1 (-6.3 – -4.0)a	-4.4 (-5.2 – -3.5)a	0.244
25 Pct Fat (%Body weight)	-3 (-4 – -2)a	-2 (-2 – -1)a	0.665
Body mass index (kg/m ²)			
30	-2.7 (-3.7 – -1.6)a	-2.3 (-2.7 – -1.9)a	0.134

Values are mean (95% confidence limits). a: analyzed using paired t-test (p<0.0001); b: analyzed

using paired t-test (p=0.002).

35 A: Subjects high in physical activity

B: Subjects low in physical activity

*: Analyzed using One-way ANOVA

The results of weight loss are shown graphically in Fig. 1 for both groups and the percentage weight loss is shown graphically in Fig. 2.

5

The results show that a weight loss generated by using the powder formulation of Example 4 is found in both groups of high physical activity as well as low physical activity.

10 Example 6

Weight loss in obese patients with knee osteoarthritis

15 Obese patients with knee OA are encouraged to reduce their body weight. Because of the musculoskeletal pain associated with physical activity among obese patients with knee OA, most of these patients lead a sedentary life with little exercise. A dietary approach to diminish the weight will be beneficial for the patients in several aspects including a reduced load on the weight bearing joints.

20 Speasy® from NutriCare A/S, having the formulation of Example 4 provided the subjects with 3.4 MJ/day (810 kcal): 37 E% from protein, 47 E% from carbohydrate and 16 E% from fat.

25 29 obese patients (Body mass index (BMI)>28 kg/m²) with knee OA who were randomized to either the LED (women/men: 13/1) or a conventional (C) hypocaloric diet (5 MJ/day) (women/men: 12/3). Their age was 65.1 ± 7.4 years (mean ± SD) and 65.7 ± 13.0 years, respectively, ranging from 45 to 90 years. The subjects' initial BMI was 36.3 ± 4.9 kg/m² and 35.3 ± 3.7 kg/m², and their lean body mass (LBM, assessed by electrical impedance) was 48.6 ± 7.5 kg and 52.4 ± 10.5 kg, respectively.

30 There was a significant weight reduction after both interventions. The LED intervention showed a reduction of 7.9 kg (95% confidence interval: 9.8 to 5.9; P<0.0001), whereas the C produced only 2.7 kg (3.9 to 1.5; P<0.001) (treatment difference P<0.0001). In the LED, the LBM decreased by 3.2 kg (3.9 to 2.5;

P<0.0001) whereas the reduction was 1.9 kg (2.8 to 0.9; P<0.01) in C (treatment difference P<0.05). Thus, comparing the change in body composition (%LBM), we found a 1.1% (0.2 to 1.9; P<0.05) increase after LED, whereas no significant change after C: -0.4% (-1.3 to 0.4; P=0.27). 40.5 % of weight loss in the LED group
5 consisted of LBM versus 70 % in the C group (P <0.02).

The LED showed a better weight reducing property, with a more favorable effect on body composition than a conventional hypocaloric diet after 8 weeks intervention.
The results of this study demonstrate the possibility of reducing weight in elderly,
10 sedentary patients, without loss of excessive lean body mass.

Claims:

1. A low-energy-diet comprising as ingredients sources of

5 protein, carbohydrate, fat, and optionally minerals and pH-regulating agents, wherein one or more of the ingredient(s) has effect on at least two of the following mechanisms

the basal metabolic rate, and/or

10 the protein metabolism, and /or
the energy expenditure,

when the low-energy-diet is administered as the main or sole nutrition.

15 2. The low-energy-diet according to claim 1, wherein the diet has an energy content in the range of from 600 kcal/d to 1200 kcal/d.

3. The low-energy-diet according to claim 2, wherein the diet has an energy content of approximately 800 kcal/d.

20 4. The low-energy-diet according to any of the preceding claims, wherein the source of protein is selected from casein, pork protein, and/or soy protein

5. The low-energy-diet according to claim 4, wherein at least a portion of the 25 source of protein is soy protein.

6. The low-energy-diet according to any of the preceding claims, wherein the diet comprises the protein source in an amount of from 50 g protein to 80 g protein.

30 7. The low-energy-diet according to claim 6, wherein the diet comprises the protein source in an amount of from 60 g protein to 75 g protein.

8. The low-energy-diet according to any of the preceding claims, wherein the diet 35 comprises the carbohydrate source in an amount of from 70 g carbohydrate to 120 g carbohydrate.

9. The low-energy-diet according to claim 8, wherein the diet comprises the carbohydrate source in an amount of from 80 g carbohydrate to 110 g carbohydrate.
- 5 10. The low-energy-diet according to any of the preceding claims, wherein at least a part of the carbohydrate source is selected from dihydroxy acetone phosphate and/or pyruvate.
- 10 11. The low-energy-diet according to claim 10, wherein the diet comprises dihydroxy acetone phosphate and/or pyruvate in an amount sufficient to increase the energy expenditure.
- 15 12. The low-energy-diet according to claim 10 or 11, wherein the diet comprises dihydroxy acetone phosphate and/or pyruvate in an amount sufficient to increase satiety.
13. The low-energy-diet according to claim 10, 11 or 12, wherein the diet comprises dihydroxy acetone phosphate in an amount of from 5 g to 15 g.
- 20 14. The low-energy-diet according to claim 10, 11, 12 or 13, wherein the diet comprises pyruvate in an amount of from 5 g to 20 g.
- 15 15. The low-energy-diet according to claim 14, wherein the pyruvate is in the form of sodium pyruvate and/or calcium pyruvate.
- 25 16. The low-energy-diet according to any of the preceding claims, wherein the diet comprises the fat source in an amount of from 5 g to 20 g.
17. The low-energy-diet according to claim 16, wherein at least 3 g of the fat source is a fat source capable of increasing the energy expenditure.
- 30 18. The low-energy-diet according to claim 17, wherein at least 3 g of the fat source is medium chain triglycerides.

19. The low-energy-diet according to claim 18, wherein the medium chain triglycerides are selected from C6 triglycerides, C8 triglycerides and C10 triglycerides.

20. The low-energy-diet according to any of the preceding claims, wherein at least

5 3 g of the fat source is fish oil.

21. The low-energy-diet according to any of the preceding claims, wherein the diet comprises pH-regulating agent in an amount sufficient to reduce protein degradation.

10

22. The low-energy-diet according to claim 21, wherein the diet comprises as the pH-regulating agent bicarbonate in an amount sufficient to reduce protein degradation.

15

23. The low-energy-diet according to claim 21, wherein the diet comprises bicarbonate in an amount of from 50 mmol/d to 70mmol/d.

24. The low-energy-diet according to any of the preceding claims, wherein diet comprises iron in an amount sufficient to modulate the basal metabolic rate.

20

25. The low-energy-diet according to claim 24, wherein the diet comprises iron in an amount sufficient to prevent reduction in the basal metabolic rate.

25

26. The low-energy-diet according to claim 24 or 25, wherein the diet comprises iron in an amount of from 20 mg/d to 30 mg/d.

27. The low-energy-diet according to any of the preceding claims, wherein the diet further comprises dietary fibres.

30

28. The low-energy-diet according to claim 27, wherein the dietary fibres are selected from barley fibres, sugar beat fibres and oat fibres.

29. The low-energy-diet according to any of the preceding claims, wherein the diet further comprises magnesium.

35

30. The low-energy-diet according to claim 29, wherein the magnesium is added as MgCl.
31. The low-energy-diet according to any of the preceding claims, wherein the diet
5 further comprises ursodeoxy cholic acid.
32. The low-energy-diet according to any of the preceding claims, wherein the diet is
in the form of powder.
- 10 33. The low-energy-diet according to claim 32, wherein the powder is capable of
being suspended or solved in liquid, such as liquid selected from water and milk.
34. The low-energy-diet according to any of the preceding claims 1-31, wherein the
diet is in the form of ready-to-drink product.
- 15 35. The low-energy-diet according to any of the preceding claims 1-31, wherein the
diet is in the form of bar product.
36. The low-energy-diet according to any of the preceding claims, wherein the diet is
suited for the main or sole nutrition daily, said diet being divided into two or more
20 portions per day.
37. The low-energy-diet according to claim 36, wherein the diet is packed in a pack-
age intended for being able to cover the total nourishment requirement for a de-
25 fined period of time.
38. A method for treating overweight comprising administering to an individual in
need thereof an effective amount of a low-energy-diet as defined in any of the
claims 1-36 as the main or sole nutrition daily.
- 30 39. Use of ingredients being sources of

protein, carbohydrate, fat, and optionally minerals and pH-regulating agents,
wherein one or more of the ingredient(s) has effect on at least two of the follow-
35 ing mechanisms

the basal metabolic rate, and/or
the protein metabolism, and /or
the energy expenditure,



5

for the production of a low-energy-diet for administration as the main or sole nutrition.

40. The use according to claim 39, wherein the ingredients are as defined in any of
10 claims 1-31.

41. The use according to claim 39 or 40, wherein the diet is in the form of a powder
or a ready-to-drink product or a bar product.

1/1

Fig. 1**Fig. 2**

INTERNATIONAL SEARCH REPORT

International application No
PCT/DK 02/00424A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A23L1/307

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A23L

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category ^o	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 425 423 A (HOEIE LARS HENRIK ;NYCOMED AS (NO)) 2 May 1991 (1991-05-02) abstract	1-9, 16-41
Y	---	10-15
Y	US 4 548 937 A (STANKO RONALD T) 22 October 1985 (1985-10-22) column 1, line 38 - line 63 abstract	10-15
X	EP 0 147 699 A (NESTLE SA) 10 July 1985 (1985-07-10) abstract	1-9, 16-41
X	WO 80 02226 A (ELAINE POWERS NUTRITION CO INC) 30 October 1980 (1980-10-30) abstract	1-9, 16-41

	-/-	

 Further documents are listed in the continuation of box C. Patent family members are listed in annex.

° Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

Date of mailing of the international search report

14 October 2003

06. 11. 2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.
Fax: (+31-70) 340-3016

Authorized officer

INGER LÖFGREN/ ELY

INTERNATIONAL SEARCH REPORT

International Application No
PCT/DE 03/00424

C.(Continuation) DOCUMENTS CONSIDERED RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 3 976 800 A (DEININGER ROLF ET AL) 24 August 1976 (1976-08-24) abstract -----	1-9, 16-41

INTERNATIONAL SEARCH REPORTInternat'l application No.
PCT/DK 03/00424**Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)**

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:

2. Claims Nos.: **1-9, 16-41**
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210

3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.

2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:

4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest The additional search fees were accompanied by the applicant's protest. No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 1-9, 16-41

Present claims relate to an extremely large number of possible compounds and methods. In fact, the claims contain so many options, that a lack of clarity and conciseness within the meaning of Article 6 PCT arises.

A very large number of food products comprise protein, carbohydrate and fat and have effect on the energy expenditure. Accordingly a complete search of all of the claims isn't possible.

However a search has been carried out for those parts of the application which appear to be clear and concise, namely claims 10 - 15.

The search has also retrieved documents which are relevant in elucidating the novelty and inventive step of claims 1-9 and 16-41. Those documents are also accounted for in the search report.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No
PCT/DK/02/00424

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0425423	A 02-05-1991	AT 120617 T DE 69018371 D1 DE 69018371 T2 DK 425423 T3 EP 0425423 A2 ES 2072413 T3 NO 904564 A	15-04-1995 11-05-1995 07-09-1995 14-08-1995 02-05-1991 16-07-1995 25-04-1991
US 4548937	A 22-10-1985	US 4351835 A AU 552442 B2 AU 8161282 A BE 891655 A1 CA 1176981 A1 CH 653891 A5 DE 3211587 A1 FI 821119 A FR 2502953 A1 GB 2095555 A ,B IT 1152769 B JP 4352718 A JP 1695935 C JP 3063531 B JP 57175117 A PT 74686 A SE 464796 B SE 8202064 A US 4415576 A US 4645764 A US 4812479 A	28-09-1982 29-05-1986 07-10-1982 16-04-1982 30-10-1984 31-01-1986 28-10-1982 02-10-1982 08-10-1982 06-10-1982 14-01-1987 07-12-1992 28-09-1992 01-10-1991 28-10-1982 01-05-1982 17-06-1991 02-10-1982 15-11-1983 24-02-1987 14-03-1989
EP 0147699	A 10-07-1985	CH 658165 A5 EP 0147699 A2 IN 160419 A1 OA 7925 A PH 20326 A ZA 8409686 A	31-10-1986 10-07-1985 11-07-1987 31-01-1987 02-12-1986 31-07-1985
WO 8002226	A 30-10-1980	US 4251550 A CA 1133315 A1 EP 0027127 A1 WO 8002226 A1	17-02-1981 12-10-1982 22-04-1981 30-10-1980
US 3976800	A 24-08-1976	LU 68000 A1 AT 325775 B AT 796273 A AU 7095874 A BE 816563 A1 CA 1034422 A1 CH 593616 A5 CH 580919 A5 DD 112347 A5 DE 2340333 A1 DE 2433266 A1 ES 428205 A1 FR 2237401 A5 GB 1438691 A JP 50048170 A ZA 7403930 A	11-04-1975 10-11-1975 15-01-1975 08-01-1976 16-10-1974 11-07-1978 15-12-1977 29-10-1976 12-04-1975 30-01-1975 24-04-1975 16-08-1976 07-02-1975 09-06-1976 30-04-1975 25-06-1975